Blood: Elderly patients with multiple myeloma can be maintained with low-dose lenalidomide after Rd induction chemotherapy

Lenalidomide-dexamethasone (Rd) is the standard treatment for elderly patients with multiple myeloma (MM)
.

However, among the patients who continued to receive Rd in the FIRST trial, one-third of the patients stopped lenalidomide, 44% of the patients needed to reduce the dose of lenalidomide, and at 18 months, only 30% had ≥75 The year-old patient is receiving the full planned dose of lenalidomide

Lenalidomide-dexamethasone (Rd) is the standard treatment for elderly patients with multiple myeloma (MM)

This is a randomized Phase 3 study, which aims to evaluate the efficacy of dose/plan-adjusted Rd following maintenance of Nalidomide 10 mg/day (Rd-R) versus Rd-continuous treatment for newly diagnosed elderly patients with MM who are moderately healthy And feasibility
.

The primary endpoint is event-free survival (EFS), defined as progression/death from any cause, lenalidomide discontinuation, or hematology grade 4 or non-hematology grade 3-4 adverse events (AE)

Event-free survival (A), progression-free survival (B) and overall survival (C) of Rd-R group and Rd group

Event-free survival (A), progression-free survival (B) and overall survival (C) of Rd-R group and Rd group

Of the 199 evaluable patients, 101 received Rd-R treatment and 98 continued Rd treatment
.

The median follow-up was 37 months

101 received Treatment Rd-R, 98 continue treatment Rd Rd-R group and the EFS Rd groups were 10.

Rd-R 3 group, and Rd group level and above the overall incidence of non-hematologic AE were 33% and 43% infection

All in all, in newly diagnosed elderly patients with moderate health, after 9 courses of Rd treatment, it is feasible to switch to reduced-dose lenalidomide maintenance therapy without dexamethasone, and the efficacy is consistent with the Rd standard maintenance program Similar

In elderly patients with newly diagnosed MM moderately healthy, after nine cycles of therapy Rd, changed without dexamethasone dose reduction of lenalidomide maintenance therapy is feasible and efficacy and Rd standard maintenance regimen similar in Among the newly diagnosed elderly patients with moderate health, after 9 courses of Rd treatment, it is feasible to switch to reduced-dose lenalidomide maintenance therapy without dexamethasone, and the curative effect is similar to the standard Rd maintenance program

Original source:

Original source:

Alessandra Larocca, et al.

Dose / schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma in this message